Alimera Sciences to Host Analyst and Investor Luncheon on Wednesday, March 25, 2015 in New York City
Management and KOLs to Discuss the Commercial Launch of ILUVIEN in the United States and Provide Business Update
ATLANTA, March 19, 2015 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced today that it will host an Analyst and Investor Luncheon on Wednesday, March 25, 2015 in New York City.
Dan Myers, Chief Executive Officer, and Rick Eiswirth, Chief Financial Officer, will be joined by Key Opinion Leaders to discuss the U.S. commercial launch of ILUVIEN, the Company's sustained release intravitreal implant used to treat patients with diabetic macular edema.
Event Details
Alimera Sciences will provide a live webcast of the event on March 25, 2015 from 12:15pm to 2:00pm ET. Interested parties may access the webcast through the Investor Relations section of the Alimera Sciences website at www.alimerasciences.com. Following the presentation, a replay of the event will be available for 30 days.
Attendance at the Alimera Sciences 2015 New York Analyst and Investor Luncheon is by invitation only.
To request an invitation for the event, please contact [email protected].
About Alimera Sciences, Inc.
Alimera Sciences, Inc., headquartered in Alpharetta, Georgia, is a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. Alimera's European operations are conducted from London by its subsidiary, Alimera Sciences Limited, which has offices in Aldershot, U.K., Berlin, Germany and Lisbon, Portugal.
Forward Looking Statements
This press release contains "forward-looking statements," within the meaning of the Private Securities Litigation Reform Act of 1995, regarding, among other things, the availability of ILUVIEN in the U.S. and the EU, Alimera's expectations regarding the hiring and training of its salesforce in the U.S., and assumptions regarding the prevalence of DME in the U.S. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual results to differ materially from those projected in its forward-looking statements. Meaningful factors which could cause actual results to differ include, but are not limited to, uncertainty as to Alimera's ability to commercialize, and market acceptance of, ILUVIEN in the U.S. and the EU, as well as other factors discussed in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Alimera's Quarterly Report on Form 10-Q for the quarter ended September 30, 2014, which is on file with the Securities and Exchange Commission (SEC) and available on the SEC's website at www.sec.gov. Additional factors may also be set forth in those sections of Alimera's Annual Report on Form 10-K for the year ended December 31, 2014 to be filed with the SEC in the first quarter of 2015. In addition to the risks described above and in Alimera's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the SEC, other unknown or unpredictable factors also could affect Alimera's results. There can be no assurance that the actual results or developments anticipated by Alimera will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Alimera. Therefore, no assurance can be given that the outcomes stated in such forward-looking statements and estimates will be achieved.
All forward-looking statements contained in this press release are expressly qualified by the cautionary statements contained or referred to herein. Alimera cautions investors not to rely too heavily on the forward-looking statements Alimera makes or that are made on its behalf. These forward-looking statements speak only as of the date of this press release (unless another date is indicated). Alimera undertakes no obligation, and specifically declines any obligation, to publicly update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.
SOURCE Alimera Sciences, Inc.
Related Links
http://www.alimerasciences.com
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article